Antinuclear antibody formation following administration of anti‐tumor necrosis factor agents in Japanese patients with psoriasis

Yanaba, Koichi; Umezawa, Yoshinori; Honda, Hiromi; Sato, Reiko; Chiba, Momoko; Kikuchi, Sota; Asahina, Akihiko; Nakagawa, Hidemi

doi:10.1111/1346-8138.13215

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…91 Topical maxcalcitol (not available in the US) ointment can be considered as an initial treatment for palmoplantar psoriasis, including palmoplantar pustulosis. 92,93 Other combination treatments. Calcipotriene ointment combined with topical tacrolimus is more efficacious than tacrolimus alone.…”

Section: Vitamin D Analoguesmentioning

confidence: 99%

Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Elmets

Korman

Prater

et al. 2021

Journal of the American Academy of Dermatology

185

181

View full text Add to dashboard Cite

Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the United States population. This guideline addresses important clinical questions that arise in psoriasis management and care and provides recommendations based on the available evidence. The treatment of psoriasis with topical agents and with alternative medicine will be reviewed, emphasizing treatment recommendations and the role of dermatologists in monitoring and educating patients regarding benefits as well as risks that may be associated. This guideline will also address the severity assessment methods of psoriasis in adults.

show abstract

Section: Vitamin D Analoguesmentioning

confidence: 99%

Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Elmets

Korman

Prater

et al. 2021

Journal of the American Academy of Dermatology

185

181

View full text Add to dashboard Cite

show abstract

“…In the patients with high ANA titers (×160 and ×640), both anti-ds-DNA and anti-Sm antibodies were negative and no symptom suggestive of SLE was seen. Because increases in ANA levels due to biologic treatment for psoriasis, especially with TNF inhibitors, were observed, [9][10][11] it is necessary to monitor ANA levels during treatment with biologics and rule out the occurrence of lupus-like syndrome.…”

Section: Discussionmentioning

confidence: 99%

Real‐world blood examination screening data before initiation of biologics for psoriasis patients

Ozaki

Ichiyama

Ito

et al. 2022

The Journal of Dermatology

View full text Add to dashboard Cite

Psoriasis is a chronic immune‐mediated inflammatory skin disease characterized by hyperproliferation of epidermal keratinocytes. Biologics have been available for the treatment of patients with refractory psoriasis since 2010 in Japan, and as of December 2021, 10 biologics were available. The Biologics Review Committee of the Japanese Dermatological Association for Psoriasis recommends blood examination tests for antinuclear antibodies (ANA), Krebs von den Lugen (KL)‐6, hepatitis B surface antigen (HBsAg), hepatitis B surface antibodies (HBsAb), hepatitis B core antibodies (HBcAb), hepatitis C virus (HCV) antibodies, HIV antibodies, human T‐cell leukemia virus (HTLV)‐1 antibodies, β‐D‐glucan, and the T‐cell spot (T‐SPOT) test before initiation of biologics at screening. In this study, we evaluated the use of biologics for 127 psoriasis patients and the blood examination screening data before initiation of biologics in the real‐world setting. Tumor necrosis factor inhibitors, interleukin (IL)‐17 inhibitors and IL‐23 inhibitors were initiated for 54 (42.5%), 36 (28.3%), and 37 (29.1%) patients, respectively. The numbers of patients positive for ANA, HBsAg, HBsAb, HBcAb, HCV antibody, HIV antibody, HTLV‐1 antibody, and T‐SPOT were 27 (21.3%), 0 (0%), 22 (17.3%), 20 (15.7%), three (2.4%), zero (0%), one (0.8%), and 4 (3.1%), respectively. The numbers of patients whose KL‐6 and β‐D‐glucan levels were higher than the reference values were seven (5.5%) and seven (5.5%), respectively. In the real‐world setting, it is sometimes unavoidable to use biologics for those patients with abnormal data although careful monitoring is necessary.

show abstract

Increase in antinuclear antibody levels through biologic treatment for psoriasis

Miki

Endo

Naka

et al. 2018

The Journal of Dermatology

View full text Add to dashboard Cite

Antinuclear antibody formation following administration of anti‐tumor necrosis factor agents in Japanese patients with psoriasis

Cited by 4 publications

References 5 publications

Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Joint AAD–NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures

Real‐world blood examination screening data before initiation of biologics for psoriasis patients

Increase in antinuclear antibody levels through biologic treatment for psoriasis

Contact Info

Product

Resources

About